Cellectar Biosciences, Inc.
CLRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001279704
No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Cellectar Biosciences, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +2 vs. Q2 2025
- Shares held
- 296.2K
- +192.8K (+186.4%) vs. Q2 2025
- Total value
- $1.65M
- +$916.3K (+124.8%) vs. Q2 2025
- New holders
- 6
- 7 more added
- Sold out
- 4
- 3 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLRB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 29 | $9.08M |
| Q1 2026 | 19 | $812.9K |
| Q4 2025 | 20 | $1.04M |
| Q3 2025 | 21 | $1.65M |
| Q2 2025 | 19 | $734.0K |
| Q1 2025 | 32 | $1.63M |
| Q4 2024 | 30 | $1.52M |
| Q3 2024 | 35 | $30.0M |
| Q2 2024 | 37 | $28.3M |
| Q1 2024 | 45 | $36.3M |
| Q4 2023 | 26 | $23.9M |
| Q3 2023 | 20 | $3.85M |
| Q2 2023 | 21 | $3.08M |
| Q1 2023 | 21 | $2.43M |
| Q4 2022 | 26 | $3.22M |
| Q3 2022 | 22 | $2.14M |
| Q2 2022 | 33 | $3.61M |
| Q1 2022 | 32 | $4.69M |
| Q4 2021 | 42 | $4.38M |
| Q3 2021 | 40 | $6.77M |
| Q2 2021 | 46 | $14.9M |
| Q1 2021 | 45 | $24.2M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Cellectar Biosciences, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bleichroeder LP | 100,000 | $560.0K | 0.11% | +100,000 | New |
| Vanguard Group Inc | 65,171 | $365.0K | 0.00% | +8,830+15.7% | Added |
| Renaissance Technologies LLC | 24,900 | $139.4K | 0.00% | +24,900 | New |
| Geode Capital Management, LLC | 24,892 | $139.4K | 0.00% | +10,453+72.4% | Added |
| DRW Securities, LLC | 21,101 | $118.2K | 0.01% | +21,101 | New |
| Citadel Advisors LLC | 18,526 | $103.7K | 0.00% | +18,526 | New |
| Dimensional Fund Advisors LP | 13,033 | $73.0K | 0.00% | +13,033 | New |
| Sequoia Financial Advisors, LLC | 10,783 | $60.4K | 0.00% | +10,783 | New |
| Riverview Capital Advisers, LLC | 10,384 | $50.1K | 0.01% | −116−1.1% | Reduced |
| BlackRock, Inc. | 4,745 | $26.6K | 0.00% | +3+0.1% | Added |
| Tower Research Capital LLC (TRC) | 1,090 | $6.10K | 0.00% | +895+459.0% | Added |
| UBS Group AG | 908 | $5.08K | 0.00% | −2,712−74.9% | Reduced |
| Morgan Stanley | 510 | $2.86K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 27 | $152 | 0.00% | +25+1,250.0% | Added |
| Group One Trading, L.P. | 23 | $129 | 0.00% | −33−58.9% | Reduced |
| Advisor Group Holdings, Inc. | 23 | $122 | 0.00% | +1+4.5% | Added |
| Citigroup Inc | 19 | $106 | 0.00% | +18+1,800.0% | Added |
| SBI Securities Co., Ltd. | 11 | $62 | 0.00% | 00.0% | Unchanged |
| Jones Financial Companies LLLP | 3 | $17 | 0.00% | 00.0% | Unchanged |
| US Bancorp | 3 | $17 | 0.00% | 00.0% | Unchanged |
| Danske Bank A/S | 2 | $11 | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 0 | $0 | 0.00% | −12,578−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −238−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −133−100.0% | Sold out |
| Harbour Investments, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |